BioStock Article: Aptahem reports growing buzz around Apta-1

Read the full article at Aptahem's website.

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail:
ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.

Datum 2025-04-01, kl 19:14
Källa Cision
Bifogade filer
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.